Blood· 2017Q1

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi et al.

1,476citations
Q1SCImago
2017year

Short summary

Enasidenib, at 100 mg daily, achieved a 40.3% overall response rate in patients with relapsed or refractory acute myeloid leukemia (AML), with a median response duration of 5.8 months.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine